Sameer Alharthi

1.6k total citations
41 papers, 738 citations indexed

About

Sameer Alharthi is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Sameer Alharthi has authored 41 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Toxicology. Recurrent topics in Sameer Alharthi's work include Pharmacovigilance and Adverse Drug Reactions (5 papers), Pharmaceutical studies and practices (4 papers) and Inflammatory Bowel Disease (4 papers). Sameer Alharthi is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (5 papers), Pharmaceutical studies and practices (4 papers) and Inflammatory Bowel Disease (4 papers). Sameer Alharthi collaborates with scholars based in Saudi Arabia, Egypt and United Kingdom. Sameer Alharthi's co-authors include Abdel‐Moneim M. Osman, Lateef M. Khan, Mohamed F. Elshal, Omar I. Saadah, Huda Mohammed Alkreathy, Wafaa S. Ramadan, Ahmed S. Ali, Mohamed Alaama, Robin Plevin and Laurence Cadalbert and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Scientific Reports.

In The Last Decade

Sameer Alharthi

39 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sameer Alharthi Saudi Arabia 16 273 123 112 104 95 41 738
Vikram Gota India 18 229 0.8× 63 0.5× 29 0.3× 165 1.6× 15 0.2× 90 891
Jacek Szymański Poland 13 238 0.9× 64 0.5× 68 0.6× 20 0.2× 37 0.4× 37 600
Resham L Gurung Singapore 17 422 1.5× 14 0.1× 79 0.7× 103 1.0× 99 1.0× 52 1.0k
Pankaj Patel India 20 535 2.0× 25 0.2× 55 0.5× 106 1.0× 113 1.2× 108 1.7k
Shujue Li China 18 386 1.4× 10 0.1× 91 0.8× 102 1.0× 25 0.3× 44 935
Shaza N. Al‐Holou United States 10 218 0.8× 58 0.5× 17 0.2× 35 0.3× 28 0.3× 22 619
Tore Bjerregaard Stage Denmark 22 382 1.4× 20 0.2× 22 0.2× 424 4.1× 92 1.0× 69 1.2k
Martin Czejka Austria 15 158 0.6× 16 0.1× 23 0.2× 245 2.4× 42 0.4× 70 739
Yamin Shu China 17 120 0.4× 9 0.1× 223 2.0× 207 2.0× 37 0.4× 42 872
Sheng‐Yow Ho Taiwan 21 543 2.0× 62 0.5× 13 0.1× 169 1.6× 27 0.3× 68 1.2k

Countries citing papers authored by Sameer Alharthi

Since Specialization
Citations

This map shows the geographic impact of Sameer Alharthi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sameer Alharthi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sameer Alharthi more than expected).

Fields of papers citing papers by Sameer Alharthi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sameer Alharthi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sameer Alharthi. The network helps show where Sameer Alharthi may publish in the future.

Co-authorship network of co-authors of Sameer Alharthi

This figure shows the co-authorship network connecting the top 25 collaborators of Sameer Alharthi. A scholar is included among the top collaborators of Sameer Alharthi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sameer Alharthi. Sameer Alharthi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mosli, Mahmoud, Yousef Qari, Omar I. Saadah, et al.. (2023). The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. Scientific Reports. 13(1). 1771–1771. 3 indexed citations
3.
Alharthi, Sameer, et al.. (2020). Identification of Genetic Variants Associated With Myocardial Infarction in Saudi Arabia. The Heart Surgery Forum. 23(4). E517–E523.
4.
Alharthi, Sameer, et al.. (2020). The effects of ursodeoxycholic acid on sepsis-induced cholestasis management in an animal model. Journal of Taibah University Medical Sciences. 15(4). 312–320. 6 indexed citations
5.
Osman, Abdel‐Moneim M., Huda Mohammed Alkreathy, Hamdan S. Al-malky, et al.. (2019). Cardioprotective Effect of Marine Astaxanthin on Doxorubicin-Induced Cardiotoxicity in Normal Rats. Journal of Pharmaceutical Research International. 1–11. 6 indexed citations
6.
Melguizo‐Sanchis, Dario, Yaobo Xu, Min Yu, et al.. (2018). iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors. Cell Death and Disease. 9(2). 128–128. 29 indexed citations
7.
Al‐Aama, Jumana Y., Noor Ahmad Shaik, Ahmed N. Sahly, et al.. (2017). Whole exome sequencing of a consanguineous family identifies the possible modifying effect of a globally rare AK5 allelic variant in celiac disease development among Saudi patients. PLoS ONE. 12(5). e0176664–e0176664. 16 indexed citations
8.
Hindawi, Salwa, Sameer Alharthi, Qamre Alam, et al.. (2016). Allelic variance among ABO blood group genotypes in a population from the western region of Saudi Arabia. Blood Research. 51(4). 274–274. 3 indexed citations
9.
Saadah, Omar I., et al.. (2015). Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.. PubMed. 8(12). 16000–6. 11 indexed citations
10.
Osman, Abdel‐Moneim M., Sameer Alharthi, Huda Mohammed Alkreathy, et al.. (2015). Chemosensitizing and nephroprotective effect of resveratrol in cisplatin –treated animals. Cancer Cell International. 15(1). 6–6. 36 indexed citations
11.
Alharthi, Sameer, et al.. (2015). The possible antianginal effect of allopurinol in vasopressin-induced ischemic model in rats. Saudi Pharmaceutical Journal. 23(5). 487–498. 7 indexed citations
12.
Alharthi, Sameer, et al.. (2015). Perceptions and knowledge regarding antimicrobial stewardship among clinicians in Jeddah, Saudi Arabia. Saudi Medical Journal. 36(7). 813–820. 18 indexed citations
13.
Khan, Lateef M., Sameer Alharthi, Huda Mohammed Alkreathy, Abdel‐Moneim M. Osman, & Ahmed S. Ali. (2014). Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection. Saudi Pharmaceutical Journal. 23(5). 515–522. 8 indexed citations
14.
Shaik, Noor Ahmad, Babajan Banaganapalli, Fazal Khan, et al.. (2014). Structural and Functional Characterization of Pathogenic Non- Synonymous Genetic Mutations of Human Insulin-Degrading Enzyme by In Silico Methods. CNS & Neurological Disorders - Drug Targets. 13(3). 517–532. 9 indexed citations
15.
Osman, Abdel‐Moneim M., Sameer Alharthi, Mohamed F. Elshal, et al.. (2013). Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell International. 13(1). 52–52. 55 indexed citations
16.
Osman, Abdel‐Moneim M., et al.. (2012). Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells. Molecular Medicine Reports. 12(1). 1368–1374. 17 indexed citations
17.
Khan, Lateef M., Sameer Alharthi, & Omar I. Saadah. (2012). Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharmaceutical Journal. 21(3). 261–266. 40 indexed citations
18.
Osman, Abdel‐Moneim M., et al.. (2012). Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell International. 12(1). 47–47. 73 indexed citations
19.
Saadah, Omar I., et al.. (2012). Entecavir treatment of children 2–16years of age with chronic hepatitis B infection. Arab Journal of Gastroenterology. 13(2). 41–44. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vikram Gota Breakdown of academic impact, for papers by Jacek Szymański Breakdown of academic impact, for papers by Resham L Gurung Breakdown of academic impact, for papers by Pankaj Patel Breakdown of academic impact, for papers by Shujue Li Breakdown of academic impact, for papers by Shaza N. Al‐Holou Breakdown of academic impact, for papers by Tore Bjerregaard Stage Breakdown of academic impact, for papers by Martin Czejka Breakdown of academic impact, for papers by Yamin Shu Breakdown of academic impact, for papers by Sheng‐Yow Ho
Rankless by CCL
2026